首页    期刊浏览 2024年11月24日 星期日
登录注册

文章基本信息

  • 标题:A Case of Central Serous Chorioretinopathy after Tadalafil Treatment
  • 本地全文:下载
  • 作者:Yoon, Yo Sep ; Lee, Seunghwan ; Woo, Je Moon
  • 期刊名称:Journal of the Korean Ophthalmological Society
  • 印刷版ISSN:0378-6471
  • 出版年度:2018
  • 卷号:59
  • 期号:1
  • 页码:93-97
  • DOI:10.3341/jkos.2018.59.1.93
  • 语种:Korean
  • 出版社:The Korean Ophthalmological Society
  • 摘要:Purpose

    To describe a patient who presented with central serous chorioretinopathy after 2 months of tadalafil administration without any other underlying disease or medication.

    Case summary

    A 49-year-old male patient was transferred from a local clinic with metamorphopsia and decreased visual acuity in the right eye. His visual acuity was 6/20 in the right eye and 18/20 in the left eye. The fundus examination showed a large serous detachment between the superior and inferior blood vessel arcades in the right retina. In his medical history, he used tadalafil three times a week for 2 months. His medication was then stopped, and a follow-up examination was scheduled. After 2 months, a fundus examination showed resolution of the subretinal fluid, and his corrected visual acuity recovered to 20/20.

    Conclusions

    Tadalafil (Cialis®) is a phosphodiesterase (PDE)-5 inhibitor and predominantly prescribed for the treatment of erectile dysfunction. PDE–5 inhibitors may be potent vasodilators in the retina and choroid, and may induce choroidal vessel engorgement leading to leakage across the retinal pigment epithelium and accumulation of subretinal fluid in selected patients. When making a diagnosis as central serous chorioretinopathy, the physician should confirm the causative drugs that are easy to miss, by performing a thorough review of the patient's medical history and promptly terminating the causative drugs.

  • 关键词:Central serous chorioretinopathy; Cialis®; Phosphodiesterase (PDE)-5 inhibitor; Tadalafil
国家哲学社会科学文献中心版权所有